surmount 2 tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial SURMOUNT-1: Tirzepatide Drastically Reduces Weight
Description
The medicine was approved by the U.S

Las nuevas molculas disponibles en el mercado (AGLP1 e iSGLT2) han demostrado de manera individual efecto en esas variables aparentemente por mecanismos de accin diferentes y complementarios

People taking Zepbound often discover their relationship with food changes dramatically within the first few weeks

But what are the facts behind GLP-1 use in pouchees and can the above statements be supported by real world evidence

Takeaways: The GI cluster matches trial data cleanly: nausea (37%), vomiting (16%), constipation (15%), diarrhea (13%)
